Английская Википедия:AVN-211
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Drugbox
AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7]Шаблон:Update needed
See also
References
External links
Шаблон:Antipsychotics Шаблон:Serotonin receptor modulators Шаблон:Nervous-system-drug-stub